arrow
G

Giuseppe Curigliano

European Institute of Oncology
H指数:118
被引数:7.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

HER2CLIMB-05研究总结:曲拉妥尼(Tucatinib)对比安慰剂联合曲妥珠单抗和帕妥珠单抗用于HER2阳性转移性乳腺癌的一线维持治疗的三期研究

2026-09-190
OAAI
Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

在真实世界环境中,接受过内分泌疗法和细胞周期依赖性激酶抑制剂治疗的ER阳性、HER2阴性、<em>ESR1</em>突变转移性乳腺癌患者中elacestrant的疗效

2026-09-140
OAAI
Liquid biopsy: a new window on the BRCA genes

液体活检:<em>BRCA</em>基因研究的新窗口

2026-09-090
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer

HER2低表达、HER2超低表达和HER2缺失型男性乳腺癌的分子和免疫图谱分析

Breast
IF7.9
2026-08-010
PRE
Combining circulating tumor cells and tumor-derived extracellular vesicles for prognosis stratification in patients with metastatic breast cancer

结合循环肿瘤细胞和肿瘤来源的细胞外囊泡对转移性乳腺癌患者进行预后分层

2026-08-010
OAAI
Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study

激素受体阳性、HER2阴性乳腺癌患者中第二次同侧局部区域复发的队列研究

2026-08-010
PRE
A deep learning framework for efficient pathology image analysis

深度学习框架用于高效病理图像分析

2026-07-010
OAAI
Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

抗体药物偶联物在特定实体瘤中的应用:基于ETOP IBCSG Partners基金会第三次研讨会成果的立场声明更新

2026-07-010
OAAI